S&P 500   4,532.76
DOW   35,028.65
QQQ   366.48
S&P 500   4,532.76
DOW   35,028.65
QQQ   366.48
S&P 500   4,532.76
DOW   35,028.65
QQQ   366.48
S&P 500   4,532.76
DOW   35,028.65
QQQ   366.48

10x Genomics Stock Forecast, Price & News

-3.05 (-3.29%)
(As of 01/19/2022 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
1.11 million shs
Average Volume
1.17 million shs
Market Capitalization
$10.01 billion
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive TXG News and Ratings via Email

Sign-up to receive the latest news and ratings for 10x Genomics and its competitors with MarketBeat's FREE daily newsletter.

10x Genomics logo

About 10x Genomics

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell ATAC for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.


See More Headlines

Industry, Sector and Symbol

Analytical instruments
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$298.85 million
Book Value
$6.81 per share


Net Income
$-542.73 million
Pretax Margin




Free Float
Market Cap
$10.01 billion

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

2.40 out of 5 stars

Medical Sector

195th out of 1,415 stocks

Analytical Instruments Industry

6th out of 33 stocks

Analyst Opinion: 3.4Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 -

10x Genomics (NASDAQ:TXG) Frequently Asked Questions

Is 10x Genomics a buy right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for 10x Genomics in the last twelve months. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" 10x Genomics stock.
View analyst ratings for 10x Genomics
or view top-rated stocks.

How has 10x Genomics' stock price been impacted by Coronavirus (COVID-19)?

10x Genomics' stock was trading at $60.76 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, TXG stock has increased by 47.5% and is now trading at $89.64.
View which stocks have been most impacted by COVID-19

When is 10x Genomics' next earnings date?

10x Genomics is scheduled to release its next quarterly earnings announcement on Wednesday, February 16th 2022.
View our earnings forecast for 10x Genomics

How were 10x Genomics' earnings last quarter?

10x Genomics, Inc. (NASDAQ:TXG) posted its quarterly earnings data on Wednesday, November, 3rd. The company reported ($0.15) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.18) by $0.03. The business had revenue of $125.30 million for the quarter, compared to the consensus estimate of $124.07 million. 10x Genomics had a negative trailing twelve-month return on equity of 6.30% and a negative net margin of 99.17%. During the same quarter in the previous year, the firm posted ($0.33) EPS.
View 10x Genomics' earnings history

What guidance has 10x Genomics issued on next quarter's earnings?

10x Genomics issued an update on its FY 2021 earnings guidance on Wednesday, November, 17th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $490 million-$500 million, compared to the consensus revenue estimate of $489.77 million.

What price target have analysts set for TXG?

7 analysts have issued 1 year price targets for 10x Genomics' stock. Their forecasts range from $24.00 to $220.00. On average, they anticipate 10x Genomics' stock price to reach $170.67 in the next year. This suggests a possible upside of 90.4% from the stock's current price.
View analysts' price targets for 10x Genomics
or view top-rated stocks among Wall Street analysts.

Who are 10x Genomics' key executives?

10x Genomics' management team includes the following people:
  • Dr. Serge Saxonov Ph.D., Co-Founder, CEO & Director (Age 44, Pay $654.99k)
  • Dr. Benjamin J. Hindson Ph.D., Co-Founder, Pres, Chief Scientific Officer & Director (Age 46, Pay $614.97k) (LinkedIn Profile)
  • Mr. Justin J. McAnear, Chief Financial Officer (Age 45, Pay $330k)
  • Mr. Bradford J. Crutchfield, Chief Commercial Officer (Age 58, Pay $350k) (LinkedIn Profile)
  • Ms. Ruth De Backer, Chief Bus. Officer (Age 44, Pay $337.81k)
  • Mr. Paul W. Wyatt, VP of Operations
  • Ms. Cassie Corneau, Mang. of Investor Relations and Strategic Fin.
  • Mr. Eric S. Whitaker, Gen. Counsel (Age 54)
  • Mr. Jonathan Schimmel, VP of Global Support & Sales Operations
  • Mr. Sam Ropp, Sr. VP of Global Sales

What is Serge Saxonov's approval rating as 10x Genomics' CEO?

25 employees have rated 10x Genomics CEO Serge Saxonov on Glassdoor.com. Serge Saxonov has an approval rating of 100% among 10x Genomics' employees. This puts Serge Saxonov in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

When did 10x Genomics IPO?

(TXG) raised $297 million in an initial public offering (IPO) on Thursday, September 12th 2019. The company issued 9,000,000 shares at $31.00-$35.00 per share. J.P. Morgan, Goldman Sachs and BofA Merrill Lynch served as the underwriters for the IPO and Cowen was co-manager.

What is 10x Genomics' stock symbol?

10x Genomics trades on the NASDAQ under the ticker symbol "TXG."

Who are 10x Genomics' major shareholders?

10x Genomics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Vigilant Capital Management LLC (0.06%), DNB Asset Management AS (0.01%), IFM Investors Pty Ltd (0.01%), Tributary Capital Management LLC (0.01%), Green Alpha Advisors LLC (0.01%) and IBM Retirement Fund (0.00%). Company insiders that own 10x Genomics stock include Associates Vi LP Venrock, Benjamin J Hindson, Benjamin J Hindson, Bradford Crutchfield, Bryan E Roberts, Foresite Capital Management I,, John R Stuelpnagel, John R Stuelpnagel, Justin J Mcanear, Justin J Mcanear, Serge Saxonov and Sridhar Kosaraju.
View institutional ownership trends for 10x Genomics

Which institutional investors are selling 10x Genomics stock?

TXG stock was sold by a variety of institutional investors in the last quarter, including IBM Retirement Fund. Company insiders that have sold 10x Genomics company stock in the last year include Benjamin J Hindson, Bradford Crutchfield, John R Stuelpnagel, Justin J Mcanear, Serge Saxonov, and Sridhar Kosaraju.
View insider buying and selling activity for 10x Genomics
or view top insider-selling stocks.

Which institutional investors are buying 10x Genomics stock?

TXG stock was acquired by a variety of institutional investors in the last quarter, including Vigilant Capital Management LLC, Tributary Capital Management LLC, DNB Asset Management AS, Spire Wealth Management, Green Alpha Advisors LLC, Newfound Research LLC, IFM Investors Pty Ltd, and Koshinski Asset Management Inc..
View insider buying and selling activity for 10x Genomics
or or view top insider-buying stocks.

How do I buy shares of 10x Genomics?

Shares of TXG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is 10x Genomics' stock price today?

One share of TXG stock can currently be purchased for approximately $89.64.

How much money does 10x Genomics make?

10x Genomics has a market capitalization of $10.01 billion and generates $298.85 million in revenue each year. The company earns $-542.73 million in net income (profit) each year or ($4.23) on an earnings per share basis.

How many employees does 10x Genomics have?

10x Genomics employs 852 workers across the globe.

What is 10x Genomics' official website?

The official website for 10x Genomics is www.10xgenomics.com.

Where are 10x Genomics' headquarters?

10x Genomics is headquartered at 6230 STONERIDGE MALL ROAD, PLEASANTON CA, 94588.

How can I contact 10x Genomics?

10x Genomics' mailing address is 6230 STONERIDGE MALL ROAD, PLEASANTON CA, 94588. The company can be reached via phone at 925-401-7300 or via email at [email protected].

This page was last updated on 1/20/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.